Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach
May T. Cho(University of California, Irvine), Farshid Dayyani(University of California, Irvine), Jennifer Brooke Valerin(University of California, Irvine), Sepideh Gholami(University of California, Davis), Ghaneh Fananapazir, Zeljka Jutric(Providence Portland Medical Center), Jason Samarasena(University of California, Irvine), Sooraj Tejaswi(Sutter Health), Nadine Abi‐Jaoudeh(University of California, Irvine), Dorina Gui(University of California, Los Angeles), Xiaodong Li(Fujian Medical University), Jacob Mercer(Helsinn Therapeutics (United States))
Cited by 21
Related Papers
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|The Lancet. Gastroenterology & hepatology|2024|245
Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy
|JAMA|2023|129
Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019
|Military Medical Research|2021|121
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
|JCO Precision Oncology|2022|72